1. Home
  2. CANF vs JDZG Comparison

CANF vs JDZG Comparison

Compare CANF & JDZG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Can-Fite Biopharma Ltd Sponsored ADR (Israel)

CANF

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

HOLD

Current Price

$0.17

Market Cap

4.8M

Sector

Health Care

ML Signal

HOLD

JDZG

JIADE LIMITED

HOLD

Current Price

$0.93

Market Cap

5.2M

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
CANF
JDZG
Founded
1994
2020
Country
Israel
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Other Consumer Services
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
4.8M
5.2M
IPO Year
N/A
2024

Fundamental Metrics

Financial Performance
Metric
CANF
JDZG
Price
$0.17
$0.93
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$3.25
N/A
AVG Volume (30 Days)
1.0M
14.9K
Earning Date
02-03-2026
04-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$560,000.00
$2,680,742.00
Revenue This Year
$461.72
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
13.19
52 Week Low
$0.23
$0.87
52 Week High
$2.33
$14.00

Technical Indicators

Market Signals
Indicator
CANF
JDZG
Relative Strength Index (RSI) 22.66 22.84
Support Level $0.26 $0.87
Resistance Level $0.30 $1.17
Average True Range (ATR) 0.02 0.10
MACD -0.01 -0.03
Stochastic Oscillator 3.41 4.27

Price Performance

Historical Comparison
CANF
JDZG

About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

About JDZG JIADE LIMITED

Jiade Ltd specializes in providing one-stop comprehensive education supporting services to adult education institutions, through a wide range of software platform and auxiliary solutions. Auxiliary solutions encompass exam administration services and teaching support services throughout the entire teaching cycle. Specifically, the company offers pre-enrollment guidance on school/major selection and application strategy development, training for entrance exams, and assistance in the application process. The company also provides offline tutoring, exam administration services, guidance on graduation thesis, and social practice assistance included in the one-stop comprehensive education supporting services in the People's Republic of China.

Share on Social Networks: